Get the Stockscreener App
15.91
0.25%
0.04
After Hours:
15.91
Takeda Pharmaceutical Co Adr stock is traded at $15.91, with a volume of 3.95M.
It is up +0.25% in the last 24 hours and down -3.11% over the past month.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
See More
Previous Close:
$15.87
Open:
$16
24h Volume:
3.95M
Relative Volume:
1.29
Market Cap:
$50.27B
Revenue:
$29.91B
Net Income/Loss:
$1.30B
P/E Ratio:
39.23
EPS:
0.4056
Net Cash Flow:
$3.49B
1W Performance:
+1.99%
1M Performance:
-3.11%
6M Performance:
+11.03%
1Y Performance:
+3.38%
1-Day Range:
$15.85
$16.02
1-Week Range:
$15.59
$16.02
52-Week Range:
$12.99
$18.89
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK vs TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
15.91 | 50.27B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.63 | 40.32B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.13 | 40.31B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.57 | 33.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
545.96 | 23.17B | 3.17B | 1.29B | 1.01B | 27.09 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-13-26 | Resumed | Morgan Stanley | Overweight |
| Apr-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-16-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-19-22 | Upgrade | Cowen | Market Perform → Outperform |
| Oct-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-19 | Initiated | Cowen | Market Perform |
| Aug-15-19 | Downgrade | Daiwa Securities | Outperform → Neutral |
View All
Takeda Pharmaceutical Co Adr Stock (TAK) Latest News
Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med - Benzinga
Takeda zasocitinib beats deucravacitinib in Phase 3 psoriasis trial - grafa.com
Astellas Pharma Inc. (ALPMY) Stock Price, News, Quote & History - Yahoo Finance
Takeda Pharmaceutical (TAK) Posts Modest Gain: Support Holds, Resistance NearsDescending Triangle - newsline.com
Takeda (TAK) Edges Higher: Approaching Key Resistance Amid Steady Pharma DemandDemand Zone - newsline.com
Dell Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Takeda (TAK) Holds Steady Near Key Support Amid Defensive Sector TonePercent Above MA - newsline.com
Takeda Pharmaceutical (ADR) stock (US8740602052): shares fall in New York after shelf registration u - AD HOC NEWS
Takeda (TAK) Stock Slips 1.18% as Shares Approach Key Support AreaShort Setup Alerts - newsline.com
TAK Stock Price, Quote & Chart | TAKEDA PHARMACEUTIC-SP ADR (NYSE:TAK) - ChartMill
Takeda Pharmaceutical (TAK) Holds Steady at $16.15 Amid Sideways TradingEarnings Miss Risk - newsline.com
Takeda Pharmaceutical (TAK) Faces Resistance at $16.73, Slips 2% Amid Sector WeaknessETF Liquidity - Newser
Takeda Pharmaceutical Co Ltd (FRA:TKDA) Stock Price, Trades & News - GuruFocus
Takeda Pharmaceutical stock (JP3730800003): oncology and rare disease focus after latest earnings up - AD HOC NEWS
Earnings call transcript: Takeda beats EPS expectations in Q4 2025 - Investing.com
Earnings call transcript: Takeda beats EPS expectations in Q4 2025 By Investing.com - Investing.com Canada
Takeda Pharmaceutical stock (JP3730800003): earnings in focus as investors weigh legal risks - AD HOC NEWS
Takeda Pharmaceutical stock (JP3730800003): recent earnings and Rybelsus biosimilar plans in focus - AD HOC NEWS
Takeda Pharmaceutical Co Ltd stock (JP3730800003): earnings beat but softer EPS outlook - AD HOC NEWS
Takeda Ready to Resume Top-Line Growth With Refreshed Late-Stage Pipeline - Morningstar
Takeda Pharma ADR earnings beat by $0.03, revenue fell short of estimates - Investing.com Nigeria
Takeda Pharmaceutical stock (JP3730800003): FY2026 profit surges 77.7%, but FY2027 guidance signals - AD HOC NEWS
Takeda Surpasses Earnings Estimates Despite Revenue Miss - HarianBasis.co
What's Going On With Takeda Stock Wednesday?Takeda Pharmaceutical Co (NYSE:TAK) - Benzinga
Earnings call transcript: Takeda’s Q4 2025 performance highlights resilience - Investing.com
Takeda Pharmaceutical stock (JP3730800003): Q4 2026 earnings report released - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (FRA:TKDA) Bonds - GuruFocus
Takeda Pharmaceutical Co Ltd stock (JP3730800003): Is its rare disease focus strong enough to unlock - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (HAM:TKDA) Stock News, Headlines & Updates - GuruFocus
Takeda Pharmaceutical Co Ltd Stock Baskets - GuruFocus
Takeda Pharmaceutical (ADR) stock (US8740602052): Why Google Discover changes matter more now - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (HAM:TKDA) Competitors 2026 - GuruFocus
Takeda Pharmaceutical Co Ltd Stock Operating Data - GuruFocus
Takeda Pharmaceutical Co Ltd stock: What you should know now for smart investing - AD HOC NEWS
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Benzinga
Takeda Pharmaceutical Co Adr Stock (TAK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.20%
2.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):